代谢组学在乳腺癌生物标志物研究中的现状及展望

The current status and perspective of metabonomics in breast cancer biomarker research

代谢组学是近年来系统生物学研究领域中最活跃的分支学科之一,通过研究生命体在不同生理病理状态下所产生的内源性代谢物变化规律来揭示疾病相关的代谢本质.作为系统生物学研究中的后起之秀,代谢组学以其特独的研究视角和技术优势迅速而广泛地应用于癌症研究领域,已初步展现出广阔的临床应用前景.乳腺癌是女性最常见的恶性肿瘤,严重威胁着女性健康且呈年轻化趋势.利用代谢组学技术平台对乳腺癌进行研究,寻找潜在的代谢性生物标志物,有助于乳腺癌的早期诊断、疗效评价、预后监控及制定合适的个体化治疗方案,对改善乳腺癌患者的存活率具有重要意义.本文将对代谢组学的概念、研究方法及其在乳腺癌生物标志物研究中的应用进行综述.

Metabonomics is a developing branch of the systems biology methodology. It mainly concentrates on the metabolic variations of biological systems in various physiological and pathological states to discover the essence of abnormal metabolism. For the last decade, metabonomics has been rapidly and widely applied in cancer research with its tmique research perspective and technological advantages, which have shown a broad prospect of clinical application. Currently, breast cancer is the second most common type of cancer found overall and is prevalent in women worldwide. Metabonomics had been performed to screen potential biomarkers of breast cancer that include an early diagnosis, a therapeutic evaluation, prognostic monitoring, and individualized management, which are crucial in improving the survival rate of breast cancer patients. This review mainly presents an introduction to the concept and research techniques of metabonomics and its current status and prospect of applications in breast cancer.